ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1375

Depression and Anxiety in Psoriatic Disease: Prevalence and Associated Factors

Emily McDonough1, Arane Thavaneswaran2, Adele Carty3, Sutharshini Shanmugarajah2, Renise Ayearst4, Lihi Eder4, Vinod Chandran5, Cheryl Rosen6 and Dafna D. Gladman7, 1Medicine, University of Toronto, Ontario, ON, Canada, 2Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, 3Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, 4Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 5Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, 6Division of Dermatology, University of Toronto, Toronto western Hospital, Toronto, ON, Canada, 7Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Depression and psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment

Session Type: Abstract Submissions (ACR)

Background/Purpose: Psoriatic arthritis (PsA) affects approximately 30% of patients with psoriasis and has the potential to cause severe joint damage. Research into the prevalence of depression and anxiety in PsA patients, and the contribution of joint disease to mental health in psoriatic disease, is limited.  The objectives were: 1) To determine the prevalence of depression and anxiety in PsA patients and identify associated demographic and disease-related factors. 2) To determine if there is a difference between patients with PsA and those with psoriasis without PsA (PsC).

Methods: Consecutive patients attending PsA and PsC clinics were assessed for depression and anxiety using the Hospital Anxiety and Depression Scale (HADS). Patients with PsA satisfied CASPAR criteria and those with PsC had dermatologist confirmed psoriasis and PsA excluded by a rheumatologist. Patients underwent a clinical assessment according to a standard protocol and completed questionnaires assessing their health and quality of life. T-tests, ANOVA, univariate, and multivariate models were used to compare depression and anxiety prevalence between patient cohorts and determine factors associated with depression and anxiety.

Results: A total of 306 PsA and 135 PsC patients were assessed. The mean age of PsA and PsC patients was 53.8 and 52.4 years respectively. There were significantly more men in the PsA group (61.4% vs. 48% for PsC) and they were more likely to be unemployed (40% vs. 29.1%). The prevalence of both anxiety and depression was higher in PsA patients (36.6% and 22.2% respectively) compared to PsC (24.4% and 9.6%) (p = 0.012, 0.002). Factors associated with a higher likelihood of depression and/or anxiety included unemployment, female gender, and higher active joint count. Patient reported factors such as disability, pain, and fatigue were highly correlated with an increased likelihood of both depression and anxiety (p < 0.0001). In the univariate analyses, the protective factors for depression included having only PsC, drinking socially, and being employed. Factors associated with a higher odds ratio (OR) for depression included current smoking, a higher pain rating, higher patient reported physical disability, and a higher level of fatigue. In the multivariate reduced model, employment was protective for depression (OR 0.36) and a 1 unit increase on the fatigue severity scale (FSS) was associated with depression (OR 1.5).

Conclusion: The rate of depression and anxiety is significantly higher in PsA patients than in PsC patients. The factors most closely associated with higher rates of depression and anxiety are those in which patients express the negative effects PsA has on their quality of life, such as ratings of pain, disability and fatigue. The major limitation of this study is that it is not able to determine causation. Nonetheless, these results indicate the importance of addressing patients’ perceptions of their own health and functioning, as well as objective measures of disease severity, when treating depression and anxiety in psoriatic disease. A deeper understanding of these factors is important for planning and evaluating future treatments.


Disclosure:

E. McDonough,
None;

A. Thavaneswaran,
None;

A. Carty,
None;

S. Shanmugarajah,
None;

R. Ayearst,
None;

L. Eder,
None;

V. Chandran,
None;

C. Rosen,
None;

D. D. Gladman,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/depression-and-anxiety-in-psoriatic-disease-prevalence-and-associated-factors/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology